Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/11/2017
SIETES contiene 92128 citas

 
 
 1 a 20 de 121 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
2. Cita con resumen
Pierson-Marchandise M, Gras V, Moragny J, Micallef J, Gaboriau L, Picard S, Choukroun G, Masmoudi K, Liabeuf S, the French National Network of Pharmacovigilance Centres. The drugs that mostly frequently induce acute kidney injury: a case-noncase study of a pharmacovigilance database. Br J Clin Pharmacol 2017;83:1341-9. [Ref.ID 101945]
3. Cita con resumen
Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]
4.Tiene citas relacionadas Cita con resumen
Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Silwa K, Chazova I, Peters RJG, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Díaz R, Dans A, Dagenais G, for the HOPE-3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016;374:2032-43. [Ref.ID 100363]
5.Tiene citas relacionadas Cita con resumen
Yusuf S, Bosch J, Dagenais G, Xavier D, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJG, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sánchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Díaz R, Lonn E, for the HOPE-3 Investigators. Cholesterol lowering in intermediate. Risk persons without cardiovascular disease. N Engl J Med 2016;374:2021-31. [Ref.ID 100362]
6.Tiene citas relacionadas Cita con resumen
Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Pals P, Díaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJG, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Hung H, Dagenais G, Yusuf S, for the HOPE-3 Investigators. Blood-pressure lowering in intermediate. Risk persons without cardiovascular disease. N Engl J Med 2016;374:2009-20. [Ref.ID 100361]
7. Cita con resumen
Anónimo. Candesartan. Fetal malformations. Australia. WHO Pharmaceuticals Newsletter 2012;4:4. [Ref.ID 93675]
8. Cita con resumen
Svanström H, Pasternak B, Hvid A. Association of treatment with losartan vs candesartan and mortality among patients with heart failure. JAMA 2012;307:1506-12. [Ref.ID 92701]
9. Cita con resumen
Anónimo. Candesartan, fetal malformations and use in pregnancy. Australian Prescriber 2012;35:98. [Ref.ID 92635]
11.Enlace a cita original
Desai RJ, Ashton CM, Deswal A, Morgan RO, Mehta HB, Chen H, Aparasu RR, Johnson ML. Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiol Drug Saf 2012;21:233-40. [Ref.ID 92465]
12.
Krum H, Teerlink JR. Heart failure 2. Medical therapy for chronic heart failure. Lancet 2011;378:713-21. [Ref.ID 91440]
13.Tiene citas relacionadas Cita con resumen
Sandset EC, Bath PMW, Boysen G, Jatuzis D, Körv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, Thijs V, Berge E, on behalf of the SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011;377:741-50. [Ref.ID 90457]
14.Tiene citas relacionadas
Hankey GJ. Lowering blood pressure in acute stroke: the SCAST trial. Lancet 2011;377:696-7. [Ref.ID 90454]
15. Cita con resumen
Eklind-Cervenka M, Benson L, Dahlström U, Edner M, Rosenqvist M, Lund LH. Association of candesartan vs losartan with all-cause mortality in patients with heart failure. JAMA 2011;305:175-82. [Ref.ID 90074]
16.
Sica DA. Angiotensin receptor blockers and the risk of malignancy: a note of caution. Drug Saf 2010;33:709-12. [Ref.ID 89266]
17. Cita con resumen
Cumming J, Mays N, Daubé J. How New Zealand has contained expenditure on drugs. BMJ 2010;340:1224-6. [Ref.ID 88636]
18.Enlace a cita original
Bonet Monné S. Dades d'eficàcia dels IECA, ARA II i la combinació d'ambdós grups de fàrmacs. Butlletí d'Informació Terapèutica 2010;22:7-12. [Ref.ID 88270]
19.Enlace a cita original
Montero Corominas D, García del Pozo J, de Abajo FJ. Utilización de antihipertensivos en España, 1992-2006. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2009:1-14. [Ref.ID 86455]
20.Tiene citas relacionadas Cita con resumen
Parfrey PS. Angiotensin-receptor blockers in the prevention or treatment of microalbuminuria. Ann Intern Med 2009;151:63-5. [Ref.ID 86259]
Seleccionar todas
 
 1 a 20 de 121 siguiente >>